Shmuel Shoham, MD / Ghady Haidar, MD - What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy

Go online to PeerView.com/ERY860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Hundreds of thousands of organ transplant recipients living
in the United States, who must take immunosuppressive medication,
are at an increased risk of COVID-19 infection. Tixagevimab
co-packaged with cilgavimab has lost its emergency use
authorization as prevention for immunocompromised patients because
of its lack of efficacy against newer variants. In the absence of
prevention agents (other than vaccines) and because the prevention
of COVID-19 is shifting to a more personalized, patient-specific
approach, the complexity of clinical decision-making has increased.
Additionally, patients may face barriers in obtaining COVID-19
prevention. In this activity, based on a recent live symposium,
expert faculty and a patient advocate discuss strategies to improve
the uptake of COVID-19 prevention and increase patient and
clinician engagement and how to develop a plan to customize
COVID-19 prevention at point of care for patients needing
prevention. In addition, they look at creating strategies for
patients in order to help in overcoming real-time barriers. Upon
completion of this activity, participants should be better able to:
Improve the uptake of COVID-19 prevention and increase patient and
clinician engagement in following science-based evidence; Develop a
plan to customize COVID-19 prevention at point of care for patients
needing protection against the virus using evidence-based
recommendations and guidelines; and Facilitate patient access to
needed COVID-19 prevention by creating strategies to overcome
real-time barriers.